atogepant   Click here for help

GtoPdb Ligand ID: 9730

Synonyms: AGN-241689 | Aquipta® | example 4 [US20120122911] [1] | MK-8031 | Qulipta®
Approved drug
atogepant is an approved drug (FDA (2021), EMA (2023))
Compound class: Synthetic organic
Comment: Atogepant is an oral calcitonin gene-related peptide receptor (CGRP) antagonist that that was doscovered by Merck, and which is now being developed by Allergan as prophylaxis of migraine [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 104.29
Molecular weight 603.17
XLogP 4.39
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(c1cnc2c(c1)CC1(C2)C(=O)Nc2c1cccn2)NC1CC(C(N(C1=O)CC(F)(F)F)C)c1c(F)ccc(c1F)F
Isomeric SMILES O=C(c1cnc2c(c1)C[C@@]1(C2)C(=O)Nc2c1cccn2)N[C@H]1C[C@H]([C@H](N(C1=O)CC(F)(F)F)C)c1c(F)ccc(c1F)F
InChI InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1
1. Bell IM, Fraley ME. (2012)
Piperidinone carboxamide azaindane CGRP receptor antagonists.
Patent number: US20120122911. Assignee: Merck Sharp & Dohme Corp.. Priority date: 12/11/2010. Publication date: 17/05/2012.
2. Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J, Diamond M, Marmura MJ, Guo H, Finnegan M et al.. (2023)
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
Cephalalgia, 43 (1). [PMID:36620892]
3. Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R et al.. (2023)
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet, 402 (10404): 775-785. [PMID:37516125]
4. Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L et al.. (2022)
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Cephalalgia, 42 (1): 3-11. [PMID:34521260]